Eutilex said Thursday that it has completed registering a patent for antibody therapy, “103,” in China.The patent for “103” was registered as "Anti-Human VSIG4 Antibody and Uses Thereof." Eutilex, which has completed patient registration in the U.S. and Russia, expects to expand its business territo
OCI Holdings Chairman Lee Woo-hyun has reaffirmed the company's strategy to play a minimal role in the management of Hanmi Group following the upcoming integration with Hanmi Science.During an investor conference call on Wednesday, Chairman Lee stated that OCI Holdings intends to support Hanmi Group
JW Pharmaceutical has posted record earnings in 2023, driven by increased sales of its hyperlipidemia drugs Livalo (pitavastatin) and LivaloZet and hemophilia drug Hemlibra.JW Pharmaceutical released its preliminary operating results for the past year through a disclosure of changes in sales or prof
GC Biopharma recorded disappointing results last year due to a decline in Covid-19-related demand and the slowing exports of Hunterase amid rising geopolitical risks.GC Biopharma released its preliminary consolidated operating results for 2023 by disclosing changes in sales or profit and loss struct
Yuhan Corp. said it posted highest-ever annual sales in 2023 thanks to technology export revenue.The company reported consolidated sales and operating profit of 1.8 trillion won ($1.3 billion) and 56.7 billion won in 2023, up 4.7 percent and 57.6 percent year-on-year. Net profit also jumped 57.4 per
Bayer Korea said it has entered into a strategic partnership with Chong Kun Dang to co-market Kerendia (ingredienet: finerenone), Bayer's novel treatment for chronic kidney disease (CKD) in patients with type 2 diabetes.Kerendia received approval from the Ministry of Food and Drug Safety in May 2022
Samsung Biologics has announced a collaborative venture into the development of antibody-drug conjugate (ADC) therapies by signing a new contract development organization (CDO) agreement with LegoChem Biosciences, a Korean ADC developer.Under the accord, Samsung Biologics will participate in the ess
Led by homegrown anticancer drug Leclaza (lazertinib), Yuhan Corp. will continue its quest to become one of the top 50 global pharmaceutical companies this year. Yuhan aims to become one of the top 50 global pharmaceutical companies by 2026, its 100th founding anniversary.Yuhan Corp. CEO Cho Wook-je
Huons said it has signed a technology transfer agreement with EFIL BioScience for a functional material derived from the root vegetable parsnip, which is known for its potential benefits in supporting respiratory wellness.EFIL BioScience, established in 2021, is a Korean biotech startup focusing on
Curacle announced top-line results from its U.S. phase 2a clinical trial of CU06, an oral treatment for diabetic macular edema, on Monday."In this short-term, three-month trial, we found that CU06 blocked endothelial dysfunction and improved visual acuity, with a 5.8 increase in the number of letter
Janssen's antidepressant Spravato (esketamine) has failed to demonstrate efficacy in clinical trials in China following Japan, raising questions about its effectiveness in Koreans.The Central Pharmaceutical Review Committee under the Ministry of Food and Drug Safety (MFDS) concluded that the drugmak
Chong Kun Dang said its consolidated operating profit surged by 124.4 percent on-year to 246.6 billion won ($184.7 million) in 2023, marking a record achievement thanks to its recent licensing deal with Novartis.The company's annual revenue increased by 12.2 percent to 1.6 trillion won last year, se
Daewoong Pharmaceutical said that the company achieved its highest-ever annual performance in 2023 across three key metrics -- sales, operating profit, and operating profit margin.On a standalone basis, the company reported sales of 1.2 trillion won ($900 million), an operating profit of 133.4 billi
Ahn-gook Pharmaceutical has completed preparations to move to its new headquarters office in Gwacheon, south of Seoul, in April.Ahn-gook said Monday that it made the remaining payment of about 59.1 billion won ($44.3 million) for purchasing its Gwacheon headquarters through a correction announcement
More than seven months have passed since MSD Korea’s application for expanding coverage for 13 indications of Keytruda (pembrolizumab) was stuck in the Cancer Disease Review Committee (CDRC), prompting anxious patients to request the review of individual indications.Contrary to MSD Korea's intention
GI Cell, an affiliate of GI Innovation, has submitted an application to the Ministry of Food and Drug Safety for phase 1/2a clinical trials to evaluate the safety and efficacy of a combination therapy between GI Cell's allogeneic NK cell therapy, T.O.P. NK and GI-101A, in patients with recurrent and
Hanmi Pharm reported a groundbreaking performance for 2023, with consolidated sales and operating profit reaching 1.49 trillion won ($1.1 billion) and 220.7 billion won, up 11.97 percent and 39.5 percent from the previous year, thanks to royalties and strong domestic sales.The company also reported
LG Chem's life sciences business has hit a milestone by exceeding 1 trillion won ($755.8 million) in annual sales for the first time in the company's history. The performance was backed by strong sales from AVEO Oncology, a U.S. subsidiary acquired in April 2023. The sales represent a 30.1 percent g
Meta Fines, a drug repositioning company, said Thursday that it has signed a licensing-out agreement with BMI Korea for its cancer cachexia drug ASCA101_CC.Under the agreement, BMI Korea will co-own the global technology transfer rights of ASCA101_CC with Meta Fines and will have the right to licens
Sanofi Korea launched Aprovasc Tab, the first antihypertensive combination drug comprising irbesartan and amlodipine besylate co-developed with Handok on Thursday.Aprovasc won approval from the Ministry of Food and Drug Safety in November 2023 for treating essential hypertension in patients whose bl